Core Viewpoint - SpyGlass Pharma (SGP.US) made its debut on the US stock market with a significant opening surge of over 43%, reaching a price of $23, compared to its IPO price of $16 [1] Company Overview - SpyGlass Pharma is a late-stage biotechnology company focused on developing sustained drug delivery systems for chronic eye diseases [1] - The company's primary research product includes a system that combines a drug delivery pad with an artificial lens, targeting chronic eye conditions such as open-angle glaucoma and elevated intraocular pressure [1] Product Advantages - The treatment aims to enhance efficacy and patient compliance, presenting potential advantages over traditional daily eye drop medications [1]

周五，SpyGlass Pharma(SGP.US)登陆美股市场，开盘股价暴涨超43%，报23美元，IPO价格为16美元。 SpyGlass Pharma是一家临床后期生物技术公司，专注于开发用于慢性眼部疾病的持续药物输送系统， 旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品包括一种将药物输送 垫与人工晶状体结合的系统，用于治疗像开角型青光眼或眼压高等慢性眼病。这类治疗目标是提高疗效 和患者依从性，与传统每日滴眼药水相比有潜在优势。 ...

北京商报讯（记者 程靓）2月6日，据北京市丰台区消息，北京未来企业家促进会第一次会员大会正式 在丰台召开。据悉，为促进民营经济高质量发展，培育兼具前沿洞察力、政策把握力、资源整合力以及 强烈社会责任感的"未来企业家",丰台成功举办两期"北京未来企业家实训营"，覆盖200余名京内外的科 创型民营企业家，形成了良好的培育效应和社会影响力。在这一背景下，特发起成立"北京未来企业家 促进会"。 据介绍，未企会的成立是首都北京在"十五五"开局之年培育未来产业领军人才、激发新质生产力上迈出 的坚实一步,也标志着丰台区对民营企业的服务从阶段性培训迈向常态化、平台化、生态化的新阶段。 未来，随着各项职能的落地见效，未企会必将成为聚才、育才、兴才的重要平台，为新时代首都经济社 会高质量发展提供坚实的人才支撑与创新保障。 北京未来企业家促进会（以下简称"未企会"）作为丰台区打造的民营企业家培育品牌项目——北京未来 企业家实训营的"校友会"平台，由北京涂多多电子商务股份有限公司、北京科跃中楷生物技术有限公 司、北京首科创融科技集团有限公司等重点企业发起组建，汇聚了以北京未来企业家实训营学员为主的 近百名企业家代表，覆盖人工智能、商 ...

Summary of IN8bio Conference Call - February 05, 2026 Company Overview - **Company**: IN8bio (NasdaqGM:INAB) - **Focus**: Development of cellular therapies using gamma delta T cells - **Key Personnel**: William Ho (CEO), Dr. Larry Lamb (Chief Scientific Officer) [1][2] Core Programs and Pipeline - **Ongoing Programs**: - **INB-100**: Allogeneic cell therapy for leukemia patients undergoing transplantation, currently enrolling an expansion cohort with updated phase one data expected by year-end [3] - **INB-619**: T cell engager platform targeting CD19 for both oncology and autoimmune diseases [3] - **INB-200 and INB-400**: Genetically modified gamma-delta T cell programs targeting solid tumors, particularly glioblastoma [3][4] Glioblastoma Treatment Insights - **Mechanism of Action**: Targets the DNA damage response (DDR) pathway, which is fundamental to all cells, making it potentially applicable to various solid tumors [33] - **Clinical Trial Results**: - Patients treated with INB-200 and INB-400 showed a median progression-free survival (PFS) of 13 months, compared to 6.6 months in the control group [14] - Overall survival (OS) for treated patients reached 17.2 months, with some patients remaining progression-free for over 4 years [15][47] - No major toxicity signals or adverse events reported [11] T Cell Engager Platform - **INB-619**: A unique CD19 targeting T cell engager designed to minimize cytokine release syndrome (CRS) while effectively depleting B cells [22][27] - **Comparative Efficacy**: INB-619 demonstrated comparable or superior potency to existing B-cell depleters like Amgen's blinatumomab and Roche's mosunitumab, with a significantly wider therapeutic window [26][27] Financial and Operational Updates - **Recent Financing**: Raised $20.1 million led by Coastlands Capital, with participation from Franklin Templeton and other investors, providing runway through 2027 [28][50] - **Upcoming Milestones**: - Public peer-reviewed publication of glioblastoma data - FDA guidance on regulatory path for glioblastoma program - Mouse data for INB-619 expected by late summer [53] Additional Insights - **Market Positioning**: IN8bio has chosen not to pursue autoimmune diseases with cell therapies, focusing instead on oncology due to concerns about the safety and efficacy of existing treatments in that area [20] - **Histopathology Findings**: Analysis of treated patients showed significant infiltration of gamma-delta T cells, indicating effective targeting of tumors [19] Conclusion - IN8bio is making significant strides in the development of innovative therapies for glioblastoma and leukemia, with promising clinical results and a solid financial foundation to support ongoing research and development efforts [29]

当前，中国资产再度成为全球资本关注的焦点。 近日，景顺、富达国际、摩根士丹利基金等多家外资机构密集发布最新投资展望报告，不约而同地对中 国资产投下"信任票"，并认为在中国经济稳健复苏、股票市场估值吸引力突出以及科技创新动能持续增 强的背景下，中国资产展现出显著的长期配置价值。 经济增长保持韧性 多家外资机构对2026年中国经济增长持乐观态度，一致认为在政策有力支持下，中国经济将延续稳定向 好态势。 景顺亚太区全球市场策略师赵耀庭认为，2025年中国国内生产总值(GDP)同比增长5.0%，与预期目标相 符，经济增长主要得益于具有韧性的制造业和强劲的出口。展望2026年，预计中国经济将保持稳定增 长，动力来自人工智能相关投资加速，以及一系列旨在促进投资和提振内需消费的支持性政策的推动。 在富达国际亚洲经济学家刘培乾看来，中国宏观经济前景"日趋平衡且更具韧性"，主要得益于制造业动 能、多元化出口市场，以及颇具韧性的基础设施投资。 景顺中国内地及香港首席投资总监马磊表示，对2026年中国股票市场继续保持乐观，持续改善的基本面 及长期增长动力有望推动市场进入更可持续的结构性增长周期。其一，企业盈利已释放出明确的复苏信 ...

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth quarter 2025 Outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development expected against Q4 2024 [5][12] - Adjusted diluted EPS for Q4 was $0.62 at CER, surpassing the Outlook of approximately $0.60 [5][12] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the Outlook of 4%-5% growth [5][12] - Adjusted diluted EPS for the full year increased to $2.40 at CER, exceeding the initial Outlook by $0.12 [5][12] Business Line Data and Key Metrics Changes - Sample Technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [6][13] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [7][14] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, aided by menu expansion and a growing install base [7][14] - QIAcuity saw double-digit growth in consumables, with over 3,200 instruments installed globally [7][14] - The bioinformatics business, QIAGEN Digital Insights, continued to grow, bolstered by demand from both research and clinical customers [8][24] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [16] - In the Americas, sales declined by 1% at CER, with the U.S. market remaining flat, partly due to the government shutdown [16] - Asia-Pacific-Japan region sales were flat, with a low-teens decline in China, which represents only about 4% of total sales [16][56] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [6][34] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance Sample Technologies [9][19] - New product launches are expected to contribute significantly to growth, with QIAsymphony Connect and QIAmini targeting automation across various applications [20][68] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cautious funding and capital spending environment but expressed confidence in achieving growth targets due to a strong pipeline of new product launches [32][66] - The company anticipates gradual improvement in the funding environment throughout 2026, with expectations for mid-single-digit growth in the total market [66] - QIAGEN's 2026 Outlook includes sales growth of at least 5% at CER and adjusted EPS of at least $2.50 at CER [26][31] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and plans to continue this trend alongside selective acquisitions [9][18] - The company is reviewing its adjusted operating income margin target of at least 31% for 2028, with expectations for continued margin improvement despite headwinds from tariffs and currency movements [17][31] Q&A Session Summary Question: Insights on new product launches and growth targets - Management highlighted that new product launches are expected to open new markets and contribute to growth, with confidence in achieving the $250 million target for digital PCR by 2028 despite previous delays [37][39] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN remains focused on its growth plan and does not comment on rumors [45] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and updates will be provided as progress is made [46] Question: Margin expansion and operating leverage - Management expects significant margin improvement in 2026, driven by gross margin improvements and operational efficiency programs, despite headwinds from acquisitions and tariffs [49][50] Question: Growth outlook in China - Management confirmed limited exposure to China, with expectations for low single-digit to negative growth due to market conditions and political factors [56][57] Question: QIAstat-Dx placements and respiratory season outlook - Management expressed confidence in achieving growth targets for QIAstat-Dx, with expectations for continued relevance in respiratory testing [71][72]

Core Viewpoint - The State Administration for Market Regulation (SAMR) is promoting the internationalization of Chinese standards, aiming for high-level openness by 2025 through standard interconnectivity and cooperation with international standards organizations [2][3]. Group 1: Standardization Efforts - By 2025, SAMR aims to achieve an overall international standard conversion rate of 88.9%, with 1,510 international standards converted in that year, particularly in cultural and meteorological fields reaching a 100% conversion rate [2]. - In the "going out" aspect, SAMR plans to lead the formulation and release of 285 ISO and IEC international standards in fields such as renewable energy and traditional medicine, representing a year-on-year growth of 26.7% [2]. - Proposals for 505 international standards in biotechnology, artificial intelligence, and industrial networks will be submitted to ISO and IEC, showing a year-on-year increase of 15.8% [2]. Group 2: Language and Communication - SAMR will deploy 1,176 foreign language versions of standards in areas like "new three samples" and large complete equipment by 2025, with 441 foreign language standards published in artificial intelligence and engineering machinery [3]. - The agency will conduct specialized publicity for foreign language versions of standards through platforms like the China International Import Expo and the China-Arab States Expo, making Chinese standards more accessible globally [3]. Group 3: International Cooperation - By 2025, SAMR aims to sign multiple standardization cooperation documents with key countries, having established 130 agreements with 75 countries and organizations [3]. - The first Shanghai Cooperation Organization Standardization Cooperation Meeting and the eighth Hongqiao International Economic Forum Standard Sub-Forum have been successfully held, expanding the network of standardization cooperation [3]. - Future initiatives will include pilot projects for standard system openness, inviting international experts to participate in the construction of China's standard system, and enhancing the supply of foreign language standards in key areas [3].

Core Viewpoint - The biotechnology industry is at a crossroads, with a paradox of rising internal confidence despite external uncertainties, leading to a historical shift in treatment areas and global innovation landscape [2]. Group 1: Financing Environment - The financing environment for the biotechnology industry has shifted from enthusiasm to a rational panic, with 92% of investors expressing confidence in achieving the next investment milestone, despite a significant increase in companies seeking additional R&D funding from 14% in 2023 to 41% in 2025 [3]. - The capital allocation logic is fundamentally changing, with venture capital moving from a "broad net" strategy to "mega bets," resulting in a stark resource polarization where leading companies receive ample funding while many small and medium-sized biotech firms face liquidity crises [3][4]. Group 2: Treatment Landscape Changes - Neuroscience has emerged as the leading research focus in biotechnology, surpassing oncology for the first time, with an active rate of 44% compared to oncology's 30%, indicating a systemic shift in industry risks and technological breakthroughs [5]. - The marginal returns on oncology drug development are decreasing due to intense competition in popular targets, while breakthroughs in neuroscience related to diseases like Alzheimer's are reigniting industry ambitions [5]. Group 3: Technological Modalities - Cell therapy has become the most active technological modality at 40%, while small molecule drugs account for 28%, indicating a shift towards more complex biotechnological innovations [6]. Group 4: China's Role in Biotechnology - China is solidifying its position as a "biotechnology superpower," ranking in the top ten of the global innovation index and matching the U.S. in clinical trial numbers, presenting significant opportunities for venture capital and multinational pharmaceutical companies [7][8]. - However, the rise of China's biotechnology sector is viewed as a strategic challenge by Western governments, leading to increased regulatory scrutiny and geopolitical tensions [8]. Group 5: Talent and AI in Drug Development - The complexity of drug development and talent acquisition remains a significant concern, with talent demand in the Asia-Pacific region being three times higher than in Europe and the U.S. due to rapid industry growth [9]. - The biotechnology industry is increasingly turning to artificial intelligence (AI) and digital tools to enhance R&D efficiency, with 76% of stakeholders expecting AI to accelerate their development processes in the next two years [10].

Core Insights - The Cuban government has announced an annual investment plan totaling 1.74 trillion pesos to address urgent economic and social development needs [1] Group 1: Investment Allocation - 67% of the funds will be focused on three priority areas: food production, industrial revitalization, and the reconstruction of the electricity system [1] - 95% of the investment will be directed towards ongoing projects aimed at enhancing the self-sufficiency of strategic industries [1] Group 2: Strategic Projects - The plan includes modernization of the Antillana steel plant in collaboration with Russia, expansion of cement production capacity, and various agricultural, forestry, tobacco, and livestock projects [1] - New photovoltaic power plants and maintenance of thermal power plants are also part of the investment strategy [1] Group 3: Infrastructure and Social Welfare - The investment will cover housing, water management, tourism, and other infrastructure and social welfare areas, with plans to construct over 9,000 state-owned housing units and renovate 38 tourism hotels [1] - Upgrades to the national water supply system and support for the production of essential medicines and biotechnology research are also included [1]

Core Insights - Bio-Techne exceeded analysts' expectations for second-quarter revenue and profit, driven by strong demand for its products utilized in drug development [1] Company Performance - The company reported better-than-expected financial results for the second quarter, indicating robust operational performance [1] Market Demand - There is a significant demand for Bio-Techne's products in the drug development sector, which has positively impacted its financial outcomes [1]